



BC Centre for Disease Control  
Provincial Health Services Authority

Communicable Diseases and Immunization Service  
655 West 12th Avenue  
Vancouver, BC V5Z 4R4

Tel 604.707.2548  
Fax 604.707.2515  
[www.bccdc.ca](http://www.bccdc.ca)

**Date: November 19, 2021**

**Administrative Circular: 2021:46**

**ATTN:** Medical Health Officers and Branch Offices  
Public Health Nursing Administrators and Assistant Administrators  
Holders of Communicable Disease Control Manuals

**Re: Update to Communicable Disease Control Manual, Chapter 2: Immunization,  
Part 4 – Biological Products**

## **Part 4 – Biological Products**

### **COVID-19 Vaccines**

#### **COVID-19 Vaccine Eligibility**

- 'Pediatric populations – 5 to 11 years of age (inclusive)' has been added.

**Please remove page numbers:** 1-2 dated November 15, 2021

**Please add new page numbers:** 1-2 dated November 19, 2021

#### **COVID-19 mRNA Vaccine COMIRNATY™ (Pfizer-BioNTech) (Adult/Adolescent)**

- The product name has been updated to differentiate from the pediatric formulation.
- Doses and Schedules: Footnote A has been revised to indicate that the minimum age for vaccine receipt is based on age at presentation (i.e., the Pfizer COVID-19 vaccine adult/adolescent formulation may be offered to individuals on or after their 12th birthday).

**Please remove page numbers:** 1-6 dated November 12, 2021

**Please add new page numbers:** 1-6 dated November 19, 2021

#### **COVID-19 mRNA Vaccine COMIRNATY™ (Pfizer-BioNTech) (Pediatric)**

- This new product page has been added.

**Please add new page numbers:** 1-5 dated November 19, 2021

#### **COVID-19 Vaccine VAXZEVRIA™/COVISHIELD (AstraZeneca/Verity Pharmaceuticals)**

- Adverse Events has been updated to include rare cases of Guillain-Barré Syndrome.

**Please remove page numbers:** 1-4 dated November 12, 2021

**Please add new page numbers:** 1-4 dated November 19, 2021

**COVID-19 Vaccine (Ad26.COV2.S [recombinant]) (Janssen Inc.)**

- Adverse Events has been updated to include rare cases of Guillain-Barré Syndrome.

**Please remove page numbers:** 1-4 dated November 12, 2021

**Please add new page numbers:** 1-4 dated November 19, 2021

**Please also remove the Title Page and Table of Contents for Part 4 – Biological Products dated November 2021 and replace with the enclosed updated Title Page and Table of Contents dated November 19, 2021.**

**Supporting resources:**

**Guidance Document on the Management of Inadvertent Vaccine Errors**

Content has been added to address the management of potential inadvertent vaccine errors related to booster doses, as well as the Pfizer-BioNTech COVID-19 Vaccine Pediatric formulation (10 mcg).

If you have any questions or concerns, please contact Stephanie Meier, Senior Practice Leader, BCCDC (telephone: 604-707-2577 / email: [stephanie.meier@bccdc.ca](mailto:stephanie.meier@bccdc.ca)).

Sincerely,



Monika Naus MD MHSc FRCPC FACPM  
Medical Director  
Communicable Diseases & Immunization Service  
BC Centre for Disease Control

pc:

Provincial Health Officer  
Dr. Bonnie Henry

Dr. Reka Gustafson  
Vice President, Public Health &  
Wellness, PHSA & Deputy Provincial  
Health Officer

Deputy Provincial Health Officer  
Dr. Martin Lavoie

BC Ministry of Health, Population &  
Public Health Division:

Brian Sagar  
Senior Director Communicable  
Disease, Population and Public Health  
Division

Bernard Achampong  
Executive Director,  
Public Health, Planning and Prevention,  
Population and Public Health Division